Investor RelationsPresseCOVID-19
  1. Home
  2. Labordiagnostik 
  3. Tests nach Erkrankungen und Krankheitsbildern
  4. Leberfibrose-Test
  5. ELF Test Educational Videos

ELF Test Educational Videos

Dr. Arun Sanyal
Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health

Virginia Commonwealth University

How are you Testing your NASH Patients?

 01.07.2022

Why risk-stratification in NASH patients is so important

Medscape Education Diabetes & Endocrinology

Implementing Best Practices in Fatty Liver Disease

 23.06.2022

In this Medscape activity, Dr. Cusi summarizes key points on the diagnosis and treatment strategies of NAFLD

Dr. Zobair M. Younossi in his office
Dr. Zobair M. Younossi
Professor and Chairman of Medicine
Inova Fairfax Medical Campus, Virginia

The U.S. Economic Burden of Nonalcoholic Steatohepatitis (NASH)

 10.12.2021

Noninvasive tests provide an important tool to help reduce healthcare costs. 

Dr. Manuel Romero-Gómez
Professor of Medicine
UCM Digestive Diseases

Virgen del Rocío University Hospital; SeLiver group at Institute of Biomedicie of Seville (IBIS), University of Seville, Sevilla, Spain

Multidisciplinary Approach in the NAFLD/NASH Patient Care Pathway

 10.12.2021

An understanding of NAFLD/NASH across specialties and why the use of noninvasive tests are needed. 

Professor Jerome Boursier
Prof. Jérôme Boursier, MD, PhD
Faculty of Medicine

University of Angers, Angers, France

Noninvasive Liver Fibrosis Testing Starts in the Primary Care Setting

 10.12.2021

Turning the tide against nonalcoholic fatty liver disease (NAFLD)

Dr. Jörn Schattenberg
Professor of Medicine and Director
Metabolic Liver Research Program

University Medical Center Mainz, Germany

Redefining the NAFLD/NASH Referral Pathway: A Hepatologist's Perspective

 10.12.2021

Utility of noninvasive tests such as the ELF Test in the patient referral pathway

Dr. Scott D. Isaacs
Dr. Scott D. Isaacs, MD, FACP, FACE
Endocrinologist and Obesity Medicine Specialist

Atlanta Endocrine Associates, Atlanta, Georgia

NASH Prevalence in Type 2 Diabetes Patients and Use of Noninvasive Tests

 10.12.2021

How do endocrinologists manage type 2 diabetes patients with NAFLD/NASH?

Dr.Mazen Noureddin
Director of Fatty Liver Program

Cedars Sinai, Los Angeles, CA

Noninvasive Prognostic Tests in NASH Patient Management


 10.12.2021

How noninvasive tests such as the ELF™ Test are changing the field.

MedTech Europe, produced by BBC Story Works: Connecting the Dots video series

NAFLD Patient Pathway Story

 20.04.2021

Hear from a NAFLD patient about his journey along with the clinical experts who helped develop the pathway 

 

Medscape-Fortbildung zur Gastroenterologie

Evolution of Diagnosis and Monitoring for Liver Fibrosis

 01.04.2021

In this Medscape activity, four experts discuss how timely identification of patients at risk of progression using non-invasive diagnostic tests is crucial 

Dr. Ankur Srivastava
Dr. Ankur Srivastava
Consultant Gastroenterologist and Hepatologist
Southmead Hospital, North Bristol Trust

A Novel Two-step Pathway to Detect Liver Cirrhosis Earlier

 21.08.2019

Non-invasive tests can help reduce unnecessary referrals in patients with NAFLD

Detect Liver Cirrhosis Earlier
Addressing the Rising Prevalence of Non-alcoholic Fatty Liver Disease
Dr. Zobair M. Younossi
Professor & Chairman of Medicine,
Inova Fairfax Hospital, Virginia

Addressing the Rising Prevalence of Non-alcoholic Fatty Liver Disease

 16.08.2019

Prevalence of NAFLD in patients with both type 2 diabetes and obesity is over 75%

Rising Prevalence NAFLD

The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.